Advertisement

Digestive Diseases and Sciences

, Volume 60, Issue 11, pp 3226–3229 | Cite as

Locally Advanced Intrahepatic Cholangiocarcinoma: Complete Pathologic Response to Neoadjuvant Chemotherapy Followed by Left Hepatic Trisectionectomy and Caudate Lobectomy

  • Thuy B. Tran
  • Chinmaya K. Bal
  • Kurt Schaberg
  • Teri A. Longacre
  • Bhupinder S. Chatrath
  • George A. Poultsides
Stanford Multidisciplinary Seminars

Case Presentation and Evolution

A 67-year-old man was initially evaluated for progressive right upper quadrant pain of several months duration. He denied jaundice, acholic stools, nausea, vomiting, or pruritus. Past medical history included prostate cancer, cholelithiasis, appendicitis, hyperlipidemia, chronic lower back pain, mild hypertension, mild asthma, and gastroesophageal reflux disease. Past surgical history included prostatectomy, cholecystectomy, and appendectomy. Family history was remarkable for a brother with prostate cancer and a sister with breast cancer. The patient had a remote history of smoking and alcohol abuse. Physical examination revealed right upper quadrant tenderness but no hepatosplenomegaly. He had mild central obesity, but no stigmata of cirrhosis. Initial laboratory findings (complete blood count and comprehensive metabolic panel) were unremarkable.

Computed tomography (CT) revealed a dominant 8.5-cm left-sided liver lesion with a satellite lesion...

Keywords

Gemcitabine Portal Vein Embolization Biliary Tract Cancer Future Liver Remnant Intrahepatic Cholangiocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

None.

References

  1. 1.
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357.CrossRefPubMedGoogle Scholar
  2. 2.
    Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.CrossRefPubMedGoogle Scholar
  4. 4.
    Farges O, Fuks D, Boleslawski E et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254:824–829; discussion 830.Google Scholar
  5. 5.
    Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817–837.CrossRefPubMedGoogle Scholar
  6. 6.
    de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–3145.CrossRefPubMedGoogle Scholar
  7. 7.
    Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2005;29:728–733.CrossRefPubMedGoogle Scholar
  8. 8.
    Manzione L, Romano R, Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology. 2007;73:311–315.CrossRefPubMedGoogle Scholar
  9. 9.
    Verderame F, Russo A, Di Leo R, et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol. 2006;17:vii68–vii72.CrossRefPubMedGoogle Scholar
  10. 10.
    Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339–1343.CrossRefPubMedGoogle Scholar
  11. 11.
    Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–398.CrossRefPubMedGoogle Scholar
  12. 12.
    Slupski MW, Szczylik C, Jasinski MK. Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol. 2007;5:36.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014;5:E88–E95.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318–324.CrossRefPubMedGoogle Scholar
  15. 15.
    Glazer ES, Liu P, Abdalla EK, Vauthey JN, Curley SA. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg. 2012;16:1666–1671.CrossRefPubMedGoogle Scholar
  16. 16.
    Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16:3048–3056.CrossRefPubMedGoogle Scholar
  17. 17.
    Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8:154–157.CrossRefPubMedGoogle Scholar
  18. 18.
    Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–1940.CrossRefPubMedGoogle Scholar
  19. 19.
    Sur MD, In H, Sharpe SM, et al. Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2014. doi: 10.1245/s10434-014-4275-4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Thuy B. Tran
    • 1
  • Chinmaya K. Bal
    • 1
  • Kurt Schaberg
    • 2
  • Teri A. Longacre
    • 2
  • Bhupinder S. Chatrath
    • 3
  • George A. Poultsides
    • 1
  1. 1.Department of SurgeryStanford University School of MedicineStanfordUSA
  2. 2.Department of PathologyStanford University School of MedicineStanfordUSA
  3. 3.Department of MedicineSequoia Regional Cancer CenterVisaliaUSA

Personalised recommendations